Wen Jin Wu

2.8k total citations
62 papers, 2.3k citations indexed

About

Wen Jin Wu is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wen Jin Wu has authored 62 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 31 papers in Oncology and 19 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wen Jin Wu's work include HER2/EGFR in Cancer Research (21 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Protein Kinase Regulation and GTPase Signaling (11 papers). Wen Jin Wu is often cited by papers focused on HER2/EGFR in Cancer Research (21 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Protein Kinase Regulation and GTPase Signaling (11 papers). Wen Jin Wu collaborates with scholars based in United States, China and Singapore. Wen Jin Wu's co-authors include Richard A. Cerione, Nishant Mohan, Dianne S. Hirsch, Milos Dokmanovic, Yi Shen, S. Sean Tu, Yukinori Endo, Yi Shen, Rui Lin and Jon W. Erickson and has published in prestigious journals such as Nature, Cell and Journal of Biological Chemistry.

In The Last Decade

Wen Jin Wu

59 papers receiving 2.3k citations

Peers

Wen Jin Wu
Feilim Mac Gabhann United States
Christina H. Stuelten United States
Raj Kumar United States
Jinah Kim United States
Yong Wan China
Yuming Liu United States
Lynn A. Cornelius United States
Boning Gao United States
Feilim Mac Gabhann United States
Wen Jin Wu
Citations per year, relative to Wen Jin Wu Wen Jin Wu (= 1×) peers Feilim Mac Gabhann

Countries citing papers authored by Wen Jin Wu

Since Specialization
Citations

This map shows the geographic impact of Wen Jin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen Jin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen Jin Wu more than expected).

Fields of papers citing papers by Wen Jin Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen Jin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen Jin Wu. The network helps show where Wen Jin Wu may publish in the future.

Co-authorship network of co-authors of Wen Jin Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wen Jin Wu. A scholar is included among the top collaborators of Wen Jin Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen Jin Wu. Wen Jin Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhu, Lei, et al.. (2024). Compact 360° Tunable Phase Shifter Using Reconfigurable Multiple Resonances With Dynamic Complex Matching. IEEE Transactions on Microwave Theory and Techniques. 73(5). 2811–2822. 2 indexed citations
3.
Endo, Yukinori, Brady T. Hickerson, Natalia A. Ilyushina, et al.. (2022). Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model. Journal of Virus Eradication. 8(4). 100307–100307. 4 indexed citations
4.
Zhao, Jun, Nishant Mohan, Ruth Nussinov, Buyong Ma, & Wen Jin Wu. (2021). Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers. Antibodies. 10(1). 7–7. 15 indexed citations
5.
Endo, Yukinori, Sarah Lyon, Yi Shen, Nishant Mohan, & Wen Jin Wu. (2019). Cell proliferation and invasion are regulated differently by EGFR and MRP1 in T-DM1-resistant breast cancer cells. Scientific Reports. 9(1). 16383–16383. 8 indexed citations
6.
Németh, Balázs Tamás, Zoltán V. Varga, Wen Jin Wu, & Pál Pacher. (2016). Trastuzumab cardiotoxicity: from clinical trials to experimental studies. British Journal of Pharmacology. 174(21). 3727–3748. 105 indexed citations
7.
Bi, Chao, Xiaoqing Miao, Shing Fung Chow, et al.. (2016). Particle size effect of curcumin nanosuspensions on cytotoxicity, cellular internalization, in vivo pharmacokinetics and biodistribution. Nanomedicine Nanotechnology Biology and Medicine. 13(3). 943–953. 84 indexed citations
8.
Yan, Haoheng, Yukinori Endo, Yi Shen, et al.. (2015). Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. Molecular Cancer Therapeutics. 15(3). 480–490. 52 indexed citations
9.
Dokmanovic, Milos & Wen Jin Wu. (2015). Monitoring Trastuzumab Resistance and Cardiotoxicity. Advances in clinical chemistry. 70. 95–130. 14 indexed citations
10.
11.
Hirsch, Dianne S., Yi Shen, Milos Dokmanovic, et al.. (2014). Insulin activation of vacuolar protein sorting 34 mediates localized phosphatidylinositol 3-phosphate production at lamellipodia and activation of mTOR/S6K1. Cellular Signalling. 26(6). 1258–1268. 16 indexed citations
12.
Fan, Ying‐Xin, Lily Wong, Michael Marino, et al.. (2013). Acquired Substrate Preference for GAB1 Protein Bestows Transforming Activity to ERBB2 Kinase Lung Cancer Mutants. Journal of Biological Chemistry. 288(23). 16895–16904. 5 indexed citations
13.
ElZarrad, M. Khair, Partha Mukhopadhyay, Nishant Mohan, et al.. (2013). Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice. PLoS ONE. 8(11). e79543–e79543. 106 indexed citations
14.
Hirsch, Dianne S. & Wen Jin Wu. (2007). Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. Expert Review of Anticancer Therapy. 7(2). 147–157. 14 indexed citations
15.
Weinberg, Wendy C., et al.. (2005). Development and regulation of monoclonal antibody products: Challenges and opportunities. Cancer and Metastasis Reviews. 24(4). 569–584. 48 indexed citations
16.
Wang, Jianbin, Wen Jin Wu, & Richard A. Cerione. (2005). Cdc42 and Ras Cooperate to Mediate Cellular Transformation by Intersectin-L. Journal of Biological Chemistry. 280(24). 22883–22891. 41 indexed citations
17.
Wu, Wen Jin, S. Sean Tu, & Richard A. Cerione. (2003). Activated Cdc42 Sequesters c-Cbl and Prevents EGF Receptor Degradation. Cell. 114(6). 715–725. 156 indexed citations
18.
Tu, S. Sean, Wen Jin Wu, Jiabin Wang, & Richard A. Cerione. (2003). Epidermal Growth Factor-dependent Regulation of Cdc42 Is Mediated by the Src Tyrosine Kinase. Journal of Biological Chemistry. 278(49). 49293–49300. 85 indexed citations
19.
Wu, Wen Jin, Rui Lin, Richard A. Cerione, & Danny Manor. (1998). Transformation Activity of Cdc42 Requires a Region Unique to Rho-related Proteins. Journal of Biological Chemistry. 273(27). 16655–16658. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026